| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Purpose: This study is aimed to evaluate the clinical and biological significance of Cripto-1 in colorectal cancer. Material and Methods: Colorectal cancer specimens were obtained from 192 patients. The Cripto-1 expression was evaluated by immunohistochemistry and clinicopathological features were statistically analyzed. Functions of Cripto-1 were investigated using Cripto-1 silencing colorectal cancer cell lines. Results: In clinicopathological analysis, the number of Cripto-1-positive cases was 68 out of 192 (35%). The Cripto-1 expression was significantly associated with worse prognosis, and was an independent prognostic factor. Cripto-1 silencing colorectal cancer cell lines reduced cell proliferation, migration and activation of Akt and MAPK signaling pathways in vitro and decreased tumor growth and lymph node metastasis in vivo. Conclusion: Cripto-1 has potential for a prognostic marker and therapeutic target in colorectal cancer.
|
